Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Fighting Cancer with Personalized Vaccines: OncoDNA and myNEO Join Forces to Unlock the Power of mRNA Therapeutics

04/07/2021 | 02:50am EDT

OncoDNA, a theranostic and genomic company specializing in precision medicine, and myNEO, an AI-driven company revolutionizing target identification within immuno-oncology, are thrilled to announce a new collaboration that will revolutionize cancer care. The two companies agreed to consolidate their core technologies to enable the production of personalized vaccines for patients who have run out of treatment options.

With the COVID-19, the field of mRNA therapeutics has been moving faster than ever before. In oncology, personalized vaccines can help fight cancer by selectively boosting the immune system. These vaccines can teach the body to recognize and eliminate tumor-specific neoantigens.

OncoDNA and myNEO will leverage their sequencing and bioinformatics technologies to identify and select the most effective neoantigens to target in a patient. While OncoDNA will perform whole genome and whole transcriptome sequencing, myNEO will handle the advanced interpretation of the sequenced data and design the optimal vaccine construct for maximum clinical benefit.

The project promises to guide patients through a completely personalized journey. The eligible patients would receive tailor-made vaccines as well as personalized follow-up by monitoring circulating tumor DNA after inoculation. With its OncoFOLLOW™ liquid biopsy, OncoDNA will help monitor the patient response and the evolution of the cancer very closely using personalized next-generation sequencing method.

OncoDNA is delighted to jump with myNEO into this ambitious project. We stand at the forefront of innovation and the challenges ahead are herculean. Together we will work towards a world where patients with a hard-to-treat disease will have the opportunity to design their personalized elixirs. It may take years before this technology becomes a reality. However, the ongoing pilot tests on patients who do not respond to any therapy are showing promising results”, commented Jean-Pol Detiffe, Chief Strategy & Innovation Officer and Founder of OncoDNA.

“Since day 1, myNEO’s mission has been to unlock the promise of immunotherapy via deep genomic and immune profiling of tumors,” described Cedric Bogaert, co-founder and CEO of myNEO. “Currently, our technology is used by biopharma partners to design the upcoming breakthrough immuno-oncology therapies. This project takes our ambition one step further in enabling OncoDNA’s vast network of clinicians and patients to directly benefit from this deep genomic and immune profiling. As such, this project holds great potential to make individualized immunotherapies more accessible to patients.”


© Business Wire 2021
Latest news "Companies"
05:59aHUAYI TENCENT ENTERTAINMENT  : Notification letter to non-registered shareholders
PU
05:59a"Economic recovery will take place in line with vaccination", say Pedro Sánchez
PU
05:59aNewcore Gold Drilling Intersects 0.85 g/t Gold Over 67.0 Metres, including 2.95 g/t Gold Over 9.0 Metres, at the Enchi Gold Project, Ghana
GL
05:58aNEWS  : Rents Grow Faster for the First Time in Eight Months
PR
05:57aTESLA  : Bitcoin hits record before landmark Coinbase listing on Nasdaq
RE
05:57aPipeChina starts building $1.3 billion gas trunk line in north China
RE
05:57aHUAYI TENCENT ENTERTAINMENT  : Change request form for registered shareholders
PU
05:57aPOLSKIE GÓRNICTWO NAFTOWE I GAZOWNICTWO S A  : PGNiG and Kraków Technology Park set to energise startups
PU
05:56aSHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Romeo Power, Inc. - RMO
PR
05:55aVENTURE  : Issue And Allotment Of Shares Pursuant To The Exercise Of Options Under The Executives' Share Option Scheme
PU
Latest news "Companies"